Oyster Point Pharma (OYST) Peer Comparison
$11.17
$0.00 (0.00%)As on 12-Jan-2023 09:30EDT
Market cap
$300 Mln
Revenue (TTM)
$20 Mln
P/E Ratio
--
P/B Ratio
2.4
Div. Yield
0 %
Edit
| Oyster Point Pharma (OYST) | Imago Biosciences Inc (IMGO) | AVEO Pharmaceuticals (AVEO) | Ayala Pharmaceuticals Inc (AYLA) | |
|---|---|---|---|---|
Market cap ($ Mln) |
300 | 1,219 | 521 | 8 |
Revenue ($ Mln) |
20 | -- | 68 | 2 |
Net Profit ($ Mln) |
-176.65 | -61.64 | -29.04 | -30.42 |
Net Margin (%) |
-1,287.59 | -8,110.13 | -42.56 | -1,755.34 |
RoE (%) |
-- | -33.13 | -88.28 | -184.49 |
Price to Earnings |
-- | -- | -- | -- |
Price-To-Book |
2.39 | 7.04 | 17.96 | 1.02 |
Income Statement ($ Mln)
| Oyster Point Pharma (OYST) | Imago Biosciences Inc (IMGO) | AVEO Pharmaceuticals (AVEO) | Ayala Pharmaceuticals Inc (AYLA) | |
|---|---|---|---|---|
|
Operating Revenue
|
24.54 | 0.00 | 38.87 | 3.51 |
|
Cost of Revenue
|
1.53 | -- | 4.74 | 3.51 |
|
Gross Profit
|
23.01 | -- | 34.14 | -3.51 |
|
Operating Expenses
|
119.67 | 42.52 | 87.11 | 39.22 |
|
Operating Profit (EBIT)
|
-96.66 | -42.52 | -49.55 | -39.22 |
|
Other Income
|
-0.27 | -0.10 | 0.26 | -- |
|
Profit before Tax
|
-100.66 | -42.31 | -53.34 | -39.48 |
|
Provision for Tax
|
-- | 0.00 | -- | -0.78 |
|
Profit after Tax (Net Income)
|
-100.66 | -42.31 | -53.34 | -40.25 |
|
Minority Interest
|
-- | -- | -- | -- |
|
Consolidated Profit
|
-100.66 | -42.31 | -53.34 | -40.25 |
Liabilities ($ Mln)
| Oyster Point Pharma (OYST) | Imago Biosciences Inc (IMGO) | AVEO Pharmaceuticals (AVEO) | Ayala Pharmaceuticals Inc (AYLA) | |
|---|---|---|---|---|
|
Shareholder's Funds
|
99.54 | 214.69 | 45.87 | 34.16 |
|
Minority Interest
|
-- | -- | -- | -- |
|
Non-Current Liabilities
|
94.28 | 0.00 | 40.74 | 0.50 |
|
Current Liabilities
|
28.80 | 10.09 | 18.73 | 6.47 |
|
Total Liabilities
|
222.62 | 224.79 | 105.34 | 1.39 |
Assets ($ Mln)
| Oyster Point Pharma (OYST) | Imago Biosciences Inc (IMGO) | AVEO Pharmaceuticals (AVEO) | Ayala Pharmaceuticals Inc (AYLA) | |
|---|---|---|---|---|
|
Non-Current Assets
|
7.37 | 3.48 | 0.61 | -38.35 |
|
Current Assets
|
215.25 | 221.30 | 104.74 | 39.74 |
|
Total Assets
|
222.62 | 224.79 | 105.34 | 34.66 |
|
Total Debt*
|
92.73 | -- | 14.14 | 0.55 |
|
Net Current Assets
|
186.45 | 211.21 | 86.01 | 33.27 |
Cashflow ($ Mln)
| Oyster Point Pharma (OYST) | Imago Biosciences Inc (IMGO) | AVEO Pharmaceuticals (AVEO) | Ayala Pharmaceuticals Inc (AYLA) | |
|---|---|---|---|---|
|
Cash From Operating Activities
|
-89.37 | -39.76 | -57.26 | -38.36 |
|
Cash Flow from Investing Activities
|
-1.49 | -129.27 | -16.87 | -0.01 |
|
Cash from Financing Activities
|
91.64 | 160.99 | 82.90 | 33.33 |
|
Net Cash Inflow / Outflow
|
0.79 | -8.04 | 8.78 | 25.56 |
Ratios
Profitability Ratios
| Oyster Point Pharma (OYST) | Imago Biosciences Inc (IMGO) | AVEO Pharmaceuticals (AVEO) | Ayala Pharmaceuticals Inc (AYLA) | |
|---|---|---|---|---|
|
ROCE (%)
|
-53.03 | -58.00 | -111.94 | -110.12 |
|
ROE (%)
|
-70.34 | -58.00 | -131.44 | -110.96 |
|
ROA (%)
|
-47.87 | -26.14 | -61.93 | -170.51 |
|
EBIT Margin (%)
|
-- | -- | -- | -- |
|
Net Margin (%)
|
-414.76 | 42,738.38 | -136.32 | -1,148.15 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- |
Growth Ratios
| Oyster Point Pharma (OYST) | Imago Biosciences Inc (IMGO) | AVEO Pharmaceuticals (AVEO) | Ayala Pharmaceuticals Inc (AYLA) | |
|---|---|---|---|---|
|
Revenue Growth (%)
|
-- | -- | 5.46 | -0.05 |
|
EBIT Growth (%)
|
-- | -- | -- | -- |
|
Net Profit Growth (%)
|
-42.74 | -137.26 | -49.90 | -33.53 |
|
EPS Growth (%)
|
-0.41 | 0.85 | 0.05 | 0.05 |
|
Book Value Growth (%)
|
-- | -- | -- | -- |
Valuation Ratios
| Oyster Point Pharma (OYST) | Imago Biosciences Inc (IMGO) | AVEO Pharmaceuticals (AVEO) | Ayala Pharmaceuticals Inc (AYLA) | |
|---|---|---|---|---|
|
Price / Earnings
|
-4.75 | -8.97 | -2.90 | -2.96 |
|
Price / Book Value
|
4.80 | 1.77 | 3.37 | 3.49 |
|
Dividend Yield (%)
|
-- | -- | -- | -- |
|
EV/EBITDA
|
-3.90 | -3.86 | -1.18 | -2.01 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- |
Solvency Ratios
| Oyster Point Pharma (OYST) | Imago Biosciences Inc (IMGO) | AVEO Pharmaceuticals (AVEO) | Ayala Pharmaceuticals Inc (AYLA) | |
|---|---|---|---|---|
|
Debt to Equity
|
0.93 | -- | 0.40 | 0.01 |
|
Short term debt to equity ratio
|
0.01 | -- | 0.00 | -- |
|
Current Ratio
|
7.47 | 21.93 | 5.59 | 6.14 |
|
Quick Ratio
|
7.26 | -- | 5.50 | -- |
|
Interest Coverage
|
-25.96 | -133.74 | -12.25 | -157.81 |
Operating Efficiency Ratios
| Oyster Point Pharma (OYST) | Imago Biosciences Inc (IMGO) | AVEO Pharmaceuticals (AVEO) | Ayala Pharmaceuticals Inc (AYLA) | |
|---|---|---|---|---|
|
Debtors to sales (%)
|
27.12 | -- | 25.24 | 0.00 |
|
Asset Turnover
|
0.12 | 0.00 | 0.45 | 0.15 |
|
Receivable days
|
99.07 | -- | 51.71 | 35.47 |
|
Inventory Days
|
1,457.65 | -- | 127.69 | -- |
|
Payable days
|
1,050.84 | -- | 234.86 | 361.50 |
|
Cash Conversion Cycle
|
505.88 | -- | -55.46 | -- |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
